Asterias Biotherapeutics Inc. Series A
AST
AST was delisted on the 7th of March, 2019.
39 hedge funds and large institutions have $16.7M invested in Asterias Biotherapeutics Inc. Series A in 2015 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 12 closing their positions.
277% more capital invested
Capital invested by funds: $4.43M → $16.7M (+$12.3M)
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
7% less funds holding
Funds holding: 42 → 39 (-3)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$3.17M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.52M |
| 3 |
Millennium Management
New York
|
+$274K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$162K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$92.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Eagle Investment Management
New York
|
-$420K |
| 2 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
-$187K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$91K |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$54K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$23.2K |
AST Hedge Fund Activity: Q1 2015 in Review
39 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Series A (AST) for Q1 2015, worth a combined $16.7M — up 277% from $4.43M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of AST and 10 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 8 added.
The largest buyer was Broadwood Capital, opening a new position worth an estimated $3.17M. The largest seller was First Eagle Investment Management, cutting an estimated $420K.
- 39 institutional investors held Asterias Biotherapeutics Inc. Series A (AST) as of Q1 2015, down from 42 in Q4 2014.
- Funds reported $16.7M of Asterias Biotherapeutics Inc. Series A stock for Q1 2015, up 277% quarter-over-quarter.
- 10 funds opened new Asterias Biotherapeutics Inc. Series A positions in Q1 2015 and 12 closed out, a net change of -2 holders.
- The largest Asterias Biotherapeutics Inc. Series A buyer in Q1 2015 was Broadwood Capital, an estimated $3.17M added.
- The largest Asterias Biotherapeutics Inc. Series A seller in Q1 2015 was First Eagle Investment Management, an estimated $420K sold.
Based on aggregated 13F filings for Q1 2015.